Emerging within the UK, retatrutide, a new compound , is generating considerable excitement within the scientific community regarding its ability for body regulation. This dual GIP and GLP-1 agent agonist appears to deliver a significant improvement over existing therapies, showing positive results in initial clinical studies . Researchers retatrut